GlassScriptPhysician profile
Ryland P Byrd
NPI 1659308112
$4,039.73
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $887 · 2021: $864 · 2022: $999.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,375.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $908.85 | 2019-2022 | |
| Insmed, INC. | $192.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.45 | 2019-2022 | |
| Genzyme Corporation | $179.72 | 2019-2022 | |
| Genentech USA, INC. | $164.41 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $149.04 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $142.46 | 2020-2021 | |
| Grifols USA, LLC | $133.49 | 2019-2022 | |
| Philips North America LLC | $110.77 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.53 | 2020-2022 | |
| Circassia INC. | $66.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.30 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.05 | 2021-2022 | |
| Mylan Specialty L.P. | $45.15 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $37.64 | 2022 | |
| United Therapeutics Corporation | $23.49 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.14 | 2020 | |
| Pfizer INC. | $17.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.82 | 2021 | |
| Merck Sharp & Dohme LLC | $15.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.58 | 2019 | |
| Electromed, INC. | $15.42 | 2019 | |
| Amgen INC. | $14.28 | 2022 | |
| Inogen, INC. | $11.99 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryland Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.